Status:
COMPLETED
Wellderly Immune Antibodies Study, a Sub-Study of Healthy Elderly Active Longevity (HEAL) Cohort
Lead Sponsor:
Scripps Translational Science Institute
Conditions:
Antibodies Involved in Healthy Aging
Eligibility:
All Genders
90+ years
Brief Summary
The aim of this sub-study is to determine whether healthy individuals over 90 years of age possess immune cells that are involved in protection from chronic disease. The immune system is well known to...
Detailed Description
The aim of this sub-study is to determine whether the Wellderly posess neutralizing antibodies targeting antigens involved in chronic disease. The humoral immune system is well known to produce anti-c...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA
- Age 90 and over
- Gender: Male and Female
- Enrolled in the Healthy Elderly (HEAL) study prior to enrollment in this sub-study
- Eligible for Blood draw
- Be reliable, cooperative and willing to comply with all protocol-specified procedures.
- Able to understand and grant informed consent
- Be healthy or have mild medical conditions that may be associated with the normal aging process, including:
- Hypertension, well controlled with no more than 3 medications
- Osteoporosis or Osteopenia
- Osteoarthritis
- Benign Prostatic Hypertrophy
- Cataracts, Glaucoma or Macular Degeneration
- Dyslipidemia
- Hypothyroidism
- Pre-Diabetes/Impaired Fasting Glucose (fasting blood glucose 100-126 mg/dL, if known)
- Basal or Squamous Cell Carcinoma
- Individuals will be excluded if ANY of the following conditions apply:
- EXCLUSION CRITERIA
- Less than 90 years of age
- Currently undergoing treatment with any investigational agents or devices within 30 preceding enrollment in this study.
- Self-reported history or current diagnosis of significant chronic conditions including:
- Any Cancer (including polycythemia; excluding basal or squamous cell carcinoma
- Coronary Artery Disease, Myocardial Infarction
- Stroke or Transient Ischemic Attack (TIA)
- Deep Vein Thrombosis or Pulmonary Embolism
- Chronic Renal Disease or Hemodialysis
- Significant Auto-Immune or Inflammatory conditions such as Rheumatoid Arthritis, Lupus, Crohn's Disease, etc.
- Alzheimer's or Parkinson's Disease
- Diabetes (Hemoglobin A1C \> 6.5% or fasting glucose \> 126 mg/dL or is treated with insulin or oral diabetic medication
- Aortic or Cerebral Aneurysm
- Currently taking any of the following medications on a regular basis:
- Chemotherapeutic agents (ex. Tamoxifen, Doxorubicin, Mitoxantrone, bleomycin
- Anti-platelet or anticoagulant agents, not including Aspirin (ex. Clopidogrel/Plavix, Dipyridamole/Aggrenox/Persantine, Ticlopidine/Ticlid, Warfarin/Coumadin, Prasugrel, etc.)
- Cholinesterase inhibitor for Alzheimer's disease (ex. Donzepril/Aricept)
- Insulin or oral diabetic medication
- Individual has a significant medical condition which, in the investigator's opinion, may interfere with the individual's optimal participation in the study or would potentially confound interpretation of the individual's phenotype.
Exclusion
Key Trial Info
Start Date :
June 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01816880
Start Date
June 1 2012
End Date
May 1 2015
Last Update
October 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Scripps Translational Science Institute
La Jolla, California, United States, 92037